SCA
LCTX icon

Stonebridge Capital Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Stonebridge Capital Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29
Closed -$41 – 968
2023
Q2 		$41 Hold
29
– – ﹤0.01% 919
2023
Q1 		$44 Buy
+29
New +$40 ﹤0.01% 931

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Stonebridge Capital Advisors's LCTX Position: Q3 2023 in Review

Stonebridge Capital Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2023, closing a stake of 29 shares — an estimated $41 sold.

Stonebridge Capital Advisors first reported a position in LCTX in Q1 2023 and held it in 2 quarters. The position peaked at $44 in Q1 2023. 104 funds tracked by Wall St. Rank hold LCTX as of Q3 2023.

  • Stonebridge Capital Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 29 Lineage Cell Therapeutics shares in Q3 2023, an estimated $41.
  • Stonebridge Capital Advisors first reported a position in Lineage Cell Therapeutics in Q1 2023 and held it in 2 quarters.
  • Stonebridge Capital Advisors's Lineage Cell Therapeutics position peaked at $44 in Q1 2023.
  • 104 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.